BioLineRx Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.

Country	Israel
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	79
CEO	Philip Serlin

Contact Details

Address: Modi’in Technology Park Hevel Modi'in, 7177871 Israel
Phone	972 8 642 9100
Website	biolinerx.com

Stock Details

Ticker Symbol	BLRX
Exchange	Tel Aviv Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	IL0011015182
SIC Code	2836

Key Executives

Name	Position
Philip A. Serlin CPA, M.B.A., CPA, MBA	Chief Executive Officer
Mali Zeevi CPA, CPA	Chief Financial Officer
Dr. Ella Sorani Ph.D.	Chief Development Officer
Holly W. May M.B.A.	President of BioLineRx USA
John Lacey	Head of Corporate Communications and Investor Relations
Tsipi Keren-Lehrer B.Sc., L.L.B.	Head of BD and Strategic Advisor
Raziel Fried	Treasurer and Budgetary Control Director